Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination.

IF 0.9 Q4 CLINICAL NEUROLOGY

Case Reports in Neurological Medicine Pub Date : 2023-01-01 DOI:10.1155/2023/7061783

Marta Rodrigues de Carvalho, Myrian Mathildes Sá de Deus Rocha, Vinícius Alves Bezerra, Maciel Eduardo de Pontes, Maria Cristina Del Negro, Julio Salgado Antunes, Vinícius Viana Abreu Montanaro, Rubens Nelson Morato Fernandez

{"title":"Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination.","authors":"Marta Rodrigues de Carvalho, Myrian Mathildes Sá de Deus Rocha, Vinícius Alves Bezerra, Maciel Eduardo de Pontes, Maria Cristina Del Negro, Julio Salgado Antunes, Vinícius Viana Abreu Montanaro, Rubens Nelson Morato Fernandez","doi":"10.1155/2023/7061783","DOIUrl":null,"url":null,"abstract":"<p><p>The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.</p>","PeriodicalId":9615,"journal":{"name":"Case Reports in Neurological Medicine","volume":"2023 ","pages":"7061783"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239300/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Neurological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/7061783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.

Abstract Image

查看原文本刊更多论文

mRNA SARS-CoV-2疫苗接种后抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导的坏死性肌病

新型冠状病毒(COVID-19)大流行导致了前所未有的疫苗生产。在这方面，可能的不利影响仍有待查明和报告。在本文中，我们报告了一例年轻女性患者在接受辉瑞- biontech (BNT162b2) COVID-19疫苗后发生抗3-羟基-3-甲基戊二酰辅酶a还原酶(抗hmg - coa)免疫介导的坏死性肌炎(IMNM)。由于缺乏可能导致自身抗体产生的其他因素(药物;例如，他汀类药物)以及暴露与事件之间的时间关系。该病例报告首次提出COVID-19疫苗可能引发抗hmg - coa还原酶坏死性肌病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Neurological Medicine CLINICAL NEUROLOGY-

自引率

0.00%

发文量

审稿时长

11 weeks